unknown
Stage
2015
Founded
5
Investors
About
C4 Therapeutics develops targeted protein degraders as a new generation of medicines. The site highlights TPD (targeted protein degradation) science and clinical progress, including a Phase 1 data presentation for cemsidomide in multiple myeloma.
Explore C 4 Therapeutics, USA's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.